Biotech: Page 17
-
sanjeri via Getty Images
Sponsored by CognizantCenters of excellence or product-centric BizDevOps managed services?
As novel therapeutics become more complex — and costly — to bring to market, drug developers are looking to unified clinical development platforms to streamline operations.
Nov. 4, 2024 -
Daniel Tadevosyan via Getty Images
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck’s Longboard buyout and PTC continued a quixotic quest.
By BioPharma Dive staff • Nov. 1, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Spencer Platt via Getty Images
Jade, another biotech spinout of Paragon, to merge with Aerovate
The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate.
By Ned Pagliarulo • Oct. 31, 2024 -
Stock via Getty Images
Compass delays anticipated psilocybin readout, cuts staff
The company’s moves come after the FDA seemed to place a new hurdle in the path of psychedelic treatments for mental disorders.
By Kristin Jensen • Oct. 31, 2024 -
Jose Luis Calvo Martin & Jose Enrique Garcia-Maurino Muzquiz via Getty Images
Evommune raises $115M to accelerate immune drug tests
The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” regarding an IPO, its CEO said.
By Gwendolyn Wu • Oct. 31, 2024 -
Permission granted by Axonis Therapeutics
Investors put $115M into Axonis amid revived interest in brain drugs
The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision therapies for neurological diseases, one investor told BioPharma Dive.
By Jacob Bell • Oct. 30, 2024 -
Permission granted by Sage Therapeutics
Biogen, Sage admit a defeat in major depression
The partners no longer intend to develop Zurzuvae for one of the most common forms of depression, citing the time and cost of running new studies that would satisfy the FDA.
By Kristin Jensen • Oct. 30, 2024 -
Jacob Bell/BioPharma Dive
Biogen optimistic as new products gain traction
Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business, according to one analyst.
By Jacob Bell • Oct. 30, 2024 -
Permission granted by Archon Biosciences
A new biotech, built around protein design, springs from David Baker’s lab
Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital.
By Gwendolyn Wu • Oct. 30, 2024 -
selvanegra via Getty Images
Paragon spinout joins hunt for new type of cancer immunotherapy
Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ivonescimab, which recently beat Merck’s Keytruda in a Phase 3 trial.
By Ben Fidler • Oct. 29, 2024 -
Daniel Tadevosyan via Getty Images
Biogen refreshes its C-suite; Novartis writes down MorphoSys assets
Daniel Quirk, an immunology and neuroscience executive at Bristol Myers Squibb, will be Biogen’s next chief medical officer. Meanwhile, Robin Kramer will replace retiring CFO Michael McDonnell.
By BioPharma Dive staff • Oct. 29, 2024 -
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal
Novartis follows cross-town rival Roche in partnering with Monte Rosa Therapeutics on so-called molecular glue degraders that can target “undruggable” proteins.
By Ned Pagliarulo • Oct. 28, 2024 -
Kyodo/Newscom
After Pfizer deal, former Seagen CEO returns to lead oncology startup
David Epstein has joined Ottimo Pharma, which is developing an antibody drug that board member and longtime Roche dealmaker James Sabry claims could “change the face of cancer immunotherapy.”
By Ben Fidler • Oct. 28, 2024 -
Permission granted by Kivu Biosciences
With $92M, Kivu sets out to make ‘kinder, gentler’ ADCs
The startup claims its proprietary linker molecules can yield ADCs that are more precise and potent than existing options.
By Gwendolyn Wu • Oct. 27, 2024 -
Daniel Tadevosyan via Getty Images
GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, Roche and Dyno expanded their alliance to create better viral vectors for use in gene therapy.
By BioPharma Dive staff • Oct. 25, 2024 -
Michael M. Santiago via Getty Images
GPCR drugmaker Septerna amasses $288M in IPO
Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a treatment for hypoparathyroidism now in Phase 1 testing.
By Gwendolyn Wu • Oct. 24, 2024 -
Permission granted by BIO
Q&A // Emerging biotechJ&J’s Asish Xavier on biotech’s rebound in a volatile era
Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in the newer crop of gene and cell therapy companies.
By Gwendolyn Wu • Oct. 24, 2024 -
iStock via Getty Images
Alto hits new low as depression drug flunks key test
While analysts still see value in Alto’s approach to brain drugmaking, investors may have lost some faith, as the biotech’s shares were down by two-thirds Wednesday morning.
By Jacob Bell • Oct. 23, 2024 -
Daniel Tadevosyan via Getty Images
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market for its Fabry gene therapy.
By BioPharma Dive staff • Oct. 23, 2024 -
Permission granted by Editas Medicine
Editas, changing course again, looks to partner lead CRISPR therapy
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its treatment reni-cel.
By Ned Pagliarulo • Oct. 22, 2024 -
Jian Fan via Getty Images
Otsuka’s startup bet pays off with kidney disease drug results
A medicine the pharma acquired in a 2018 buyout of Visterra succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.
By Ben Fidler • Oct. 22, 2024 -
Christoph Burgstedt via Getty Images
Deep Dive // State of PlayRNA editing: emerging from CRISPR’s shadow
Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
By Ben Fidler , Gwendolyn Wu • Oct. 22, 2024 -
Permission granted by PureTech Health
Q&A // Emerging biotechPureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.
Shares in the Boston-based biotech creator, which had a standout success in forming Karuna Therapeutics, trade around cash levels — a "huge value disconnect" its leaders are trying to bridge.
By Jacob Bell • Oct. 21, 2024 -
Naeblys via Getty Images
Brain drug developer Seaport raises another $225M
Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.
By Jacob Bell • Oct. 21, 2024 -
FatCamera via Getty Images
Sponsored by AltasciencesPharmaceutical research on mRNA and CAR T-cell therapy in cancer: Pioneering the future of oncology
Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?
Oct. 21, 2024
Previous
